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ABSTRACT 
Interest in applications of protein crystallography to medicine was evident as the first 
high-resolution structures emerged in the 50s and 60s. In Cambridge Max Perutz and 
John Kendrew sought to understand mutations in sickle cell and other genetic diseases 
related to haemoglobin, while in Oxford the group of Dorothy Hodgkin became 
interested in long-lasting zinc-insulin crystals for treatment of diabetes and later 
considered insulin redesign as synthetic insulins became possible. The use of protein 
crystallography in structure-guided drug discovery emerged as enzyme structures 
allowed the identification of potential inhibitor-binding sites and optimisation of 
interactions of hits using the structure of the target protein. Early examples of this 
approach were the use of the structure of renin to design anti-hypertensives and the 
structure of HIV protease in design of AIDS antivirals. More recently, use of 
structure-guided design with fragment-based drug discovery, which reduces the size of 
screening libraries by decreasing complexity, has improved ligand efficiency in drug 
design and has been used to progress three oncology drugs through clinical trials to 
FDA approval. We exemplify current developments in structure-guided target 
identification and fragment-based lead discovery with efforts to develop new 
antimicrobials for mycobacterial infections. 
 
Early Development of Structure-guided Drug Discovery 
When Max Perutz, John Kendrew and their colleagues in Cambridge were solving the 
first protein structures of myoglobin and haemoglobin in the 1950s and 60s[1-3], they 
were already aware of the importance of their work to medicine. Understanding the 
impacts of mutations on oxygen affinity and subunit cooperativity in abnormal 
haemoglobins that resulted in inherited single-gene disorders, such as sickle-cell 
disease, was recognised as a major objective. Dorothy Hodgkin’s Oxford laboratory 
collaborated with Jørgen Schlichtkrull of Novo to understand how different crystalline 
forms of insulin could be exploited as slow-acting therapeutics for the treatment of 
diabetes[4]. This became a real possibility when the structure of insulin was solved[5, 
6], as many insulin sequences had been defined in Fred Sanger’s laboratory in 
Cambridge[7]. Sequences and structures stimulated ideas not only about insulin 
storage and receptor binding, but also about producing more effective therapeutics. 
These speculations became real opportunities when groups in Aachen, New York and 
Shanghai completed the synthesis of insulin, encouraging ideas about the design of 
novel synthetic insulins. 
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Ideas about drug design were stimulated by the determination of the first enzyme 
structures – lysozyme, chymotrypsin and trypsin – in the 60s and an emerging 
understanding of the interactions that led to selectivity of enzyme substrate binding[8]. 
In the 70s and 80s, clinically important drug targets such as the aspartic protease 
renin[9, 10], which cleaves angiotensinogen to form angiotensin I, an essential step in 
regulating blood pressure, were modelled on less exciting enzymes such as fungal 
pepsins [11, 12]. The use of protein crystallography in drug discovery accelerated in 
the 1980s, especially by using a combination of protein structure and interactive 
computer graphics, such as the Evans and Sutherland machines[13]. The model of 
renin[14] was used widely in structure-guided drug design in the pharma industry in 
the 1980s.  The high-resolution X-ray structures of apo-enzymes and complexes of 
renin and its close homologues followed much later[15, 16].  
 
New Paradigm of Structure-guided Drug Discovery: Targeting HIV Protease 
Probably the most influential development was the design of AIDS antivirals, based 
on the structure of HIV protease; these moved onto the market very quickly in the 
1990s. Some basic science influenced this! In 1978, Jordan Tang who had sequenced 
pepsin together with crystallographic collaborators suggested that proteases had 
evolved from an ancestral dimer by gene duplication, fusion and divergence to give 
more effective enzymes[17]. A close relative of this dimeric ancestral aspartic 
protease was found in the retroviral proteases, first in Rous Sarcoma Virus, but then in 
HIV soon after the AIDS epidemic was recognised in the US and Europe. The genome 
of HIV, which encodes a polyprotein, was shown to include a protease[18], which was 
quickly recognised as a dimeric viral protease essential for the generation of infectious 
viral particles, and a model was produced based on the aspartic proteinase 
evolutionary relationship[19]. In 1989 structures followed for Rous Sarcoma Virus   
[20, 21] and HIV protease[22, 23], the structure of which was improved by further 
experimental structures determined independently by two labs[24] [25]. The 
subsequent development of new AIDS antivirals by 1997, including four very 
successful drugs (Roche Pharmaceuticals’ saquinavir, Abbot’s ritonavir, Merck’s 
indinavir, and Agouron’s nelfinavir) demonstrated the importance of understanding 
the genome not only in terms of functions of gene products, but also their architectures 
for use in structure-guided drug discovery, recorded recently in an excellent history of 
macromolecular crystallography and its fruits[26]  
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The identification of HIV protease as a target and the development of AIDS antivirals 
was a new paradigm in drug discovery. It demonstrated that there was value in 
computational analysis of genomes in order to identify targets. This was an 
“exploration of biological space”, an exciting challenge in the early 1990s as the 
sequence determination of human infectious agents such Mycobacteriaceae that give 
rise to tuberculosis and leprosy, as well as the very much larger genome of Homo 
sapiens became real prospects. The HIV protease inhibitor story also illustrated the 
importance “exploring chemical space”: using protein structure to estimate the 
druggability of potential targets, followed by exploration of possible binding using 
screening libraries of chemical compounds. This idea of drug discovery can be 
summarised, as in Figure 1A. 
Over the subsequent 25 years, several new approaches have been introduced that 
exploit knowledge of the architecture of the target and screening of chemical libraries. 
One of the most influential has been the development of structure-guided fragment-
based drug discovery. 
 
Protein Crystallography, Fragment-Based Drug Discovery and Oncology 
In the 1980s and 90s meeting the challenge of the size and diversity of “chemical 
space” became a focus in the pharmaceutical industry with the realisation that 
chemical libraries of several thousand drug-like compounds explored only a tiny area 
of the chemical space. In order to estimate the number, Lipinski rules assuming a 
molecular weight limit of 500 daltons, the presence of carbon, hydrogen, oxygen, 
nitrogen and sulfur, and a maximum of 4 rings leads to an estimate of 10
63
[27]. Big 
pharma searched the world for new chemical diversity, often using the products of our 
natural environment in underdeveloped-forested areas. The chemical libraries grew to 
hundreds of thousands of compounds and screening was roboticized to cope with the 
challenge. But a solution to the challenge was also found in a different approach in 
which complexity of the chemicals screened was reduced by decreasing their 
molecular weights, which at the same time increased their promiscuity in binding 
targets. The innovation that allowed decrease of size of the chemical screening library 
was fragment-based drug discovery (FBDD). 
In FBDD, a fragment library often of ~ 1000 compounds of <300 Da is screened 
against the target of interest, resulting in identification of initial hits. These are then 
moved to lead candidates by chemically growing or linking the fragments followed by 
optimisation of interactions, thereby exploring the chemical space available for 
binding to the target protein very effectively. A high-affinity lead molecule thus 
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developed from a fragment hit retains the key binding interactions of the original 
fragment with the “hotspot” on the target protein. Most of the fragments have lower 
potency than the more complex molecules found in typical high-throughput screening 
(HTS) compound libraries, however small fragments that bind, do so by making well 
defined and directional high-quality interactions and by displacing unhappy water 
molecules at the hotspots, giving rise to high ligand efficiency[28].  
Early experiments used ligand-based NMR (Steve Fesik and his colleagues at Abbott) 
[29] and X-ray crystal screening[30, 31], developed at Astex initially by exploiting 
high-throughput analysis of cocktails of six to ten fragments soaked into apo-protein 
crystals.  Knowledge of the structure of the complex of the fragment with target 
protein allowed the initial use of small, often non-chiral compounds, which were 
optimized using structure-guided approaches to make specific interactions and to 
introduce chirality in the molecules. The resulting fragment hits were capable of 
achieving high binding efficiency per atom and often better physicochemical 
properties in comparison to those from HTS approach which exploits much larger 
libraries of ~10
6
 or more compounds[30, 32]. 
The relatively low affinities mean that a combination of biochemical, biophysical and 
structural techniques must be used to monitor hit identification, validation and 
subsequent elaboration into lead molecules, as summarised in Figure 1B. The choice 
of methods will depend on factors such as the availability of a sensitive biochemical 
assay, the solubility and stability of the protein, the existence of crystals of the apo-
protein, and so on. Many groups use a two-stage approach of high-throughput 
screening of the fragment library using fluorescence-based thermal shift 
measurements[32, 33], ligand-based NMR, surface plasmon resonance (SPR) and 
increasingly with the roboticized screening facilities available on synchrotron 
beamlines, X-ray crystallographic screening. The fragment hits common between 
these techniques are then validated by optimisation of resolution of the structures by 
X-ray diffraction or structure determination by NMR if not possible to define by X-ray 
methods, as well as defining the kinetics with SPR and the thermodynamics of the 
binding using isothermal calorimetry. The combination of these techniques and others 
(Figure 1B) gives reassurance of the quality of the hit. The validated fragment hits are 
then elaborated iteratively by growing to a larger molecular weight or by linking using 
structure-guided techniques. 
Where a crystal structure is not available, several labs have used fragment libraries to 
search chemical space using methods such as SPR[34], sometimes with many 
thousands of chiral compounds, often derived from analysis of successful drugs[35]. 
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Where an experimental structure or computational homology model is available, the 
pipeline can be complemented by substructure searches on commercially available 
compound databases or in-silico screening predictions of analogues[36, 37]. An 
example of this approach was that of Winter et al. [38], who had no suitable crystal 
structure to identify hits that disrupt the interaction between hepatocyte growth 
factor/scatter factor N-terminal fragment and the hepatocyte growth factor receptor 
(Met), and subsequently inhibit Met signalling. They carried out sub-structure 
searches on initial hits identified by biophysical methods such as SPR, and followed 
these by in-silico docking predictions to identify compounds, with significant anti-
tumorigenic and anti-migratory activity in cell-based assays. 
In 2011 the first fragment-derived drug, Vemurafenib, was approved targeting a 
mutant form of BRAF, extending life for patients with skin cancer. The drug was 
discovered at Plexxikon and developed in partnership with Roche. The second drug, 
Venetoclax, developed by AbbVie and Genentech, binds to BCL-2 and blocks its 
interaction with other proteins; was approved by the US FDA in 2016 for chronic 
lymphocytic leukemia (CLL). In 2017 the third drug, Ribociclib, by Astex and 
Novartis was approved for targeting the protein kinase Cdk4 and will be used in 
combination with letrozole as a first-line treatment for advanced breast cancer. All of 
these campaigns featured an important role for structure-guided approaches with a 
combination of activity in relatively small companies, often founded by academics 
with an interest in protein structure, but developed as cancer therapeutics with strong 
scientific and financial involvement of large pharma. 
 
Moving Structure-guided Discovery from Oncology to other Diseases 
We have shown that the HIV protease paradigm exploiting a combination of efficient 
exploration of biological space by understanding the genome and structural proteome, 
together with exploration of chemical space using structure-guided and fragment-
based approaches, works well in cancer. As described above, FBDD has not only 
provided useful leads but also led to drugs that have been approved by the FDA. Much 
of the work has been done in biotech and small pharma companies in collaboration 
with large pharma.  
We now address the question as to how far this structure-guided approach can be used 
to target diseases that are rare in the West, where big pharma finds it more difficult to 
get returns on its investment. These include genetic diseases occurring in a few 
families, for example cystic fibrosis or black bone disease (alkaptonuria), or those 
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infectious diseases that are mainly found in developing countries, such as tuberculosis 
and leprosy. Large pharma finds these diseases more challenging to address, as the 
financial returns on investment are limited either by the small numbers of patients or 
by the difficulty in finding a market in relatively less prosperous countries in Africa, 
South America and the Indian subcontinent. 
Structure-guided approaches will depend on knowledge of the genomes and strain 
variation of the causative organism in order to develop a fruitful/successful target-
based approach. This is being addressed worldwide, mainly by charitable initiatives 
such as the Wellcome Trust at their Genome Campus or the Bill & Melinda Gates 
Foundation in initiatives such as HIT-TB and Shorten-TB. There is also considerable 
activity in Government-funded institutes such as NIH as well as academia, for 
example the London School of Hygiene and Tropical Medicine in the UK. Some 
companies, such as GlaxoSmithKline, have active research programmes in infectious 
disease, while several are involved with academic institutions in the TB Drug 
Accelerator (TBDA) partnership, supported by the Bill &Melinda Gates Foundation. 
Here we focus on infectious diseases caused by mycobacteria to illustrate the way that 
structure-guided lead discovery in academia can use its experience in early lead 
discovery built on biochemistry, medicinal chemistry and structural biology, together 
with microbiology and human medicine. We show how knowledge of protein structure 
is central not only to select targets (exploring biological space) but also to develop 
new leads (exploring chemical space). 
 
Genomes of Mycobacteriaceae 
The Mycobacteriaceae family comprises 174 known species of acid-fast bacteria with 
high GC content and much thicker hydrophobic outer cell walls (containing mycolic 
acids) than most other bacteria [http://www.bacterio.net/mycobacterium.html]. The 
family includes several pathogenic bacteria such as Mycobacterium tuberculosis (Mtb, 
the causative agent of tuberculosis), Mycobacterium leprae (Mlep, causes leprosy), 
Mycobacterium abscessus (Mab, rapid-growing opportunistic pathogen that causes 
chronic lung diseases) and free-living non-pathogenic bacteria such as Mycobacterium 
smegmatis.  
Mtb, found in Homo sapiens, is an obligate pathogen, which has evolved with humans 
over many thousands of years. According to the most recent WHO report, 10.4 million 
people were diagnosed with tuberculosis (TB) and 1.4 million died because of the 
infection in 2015, and an additional 0.4 million TB deaths have been reported among 
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HIV-positive patients (WHO global TB reports 2016) [39]. Current first-line therapy 
for drug-sensitive TB involves a combination of four drugs (isoniazid, rifampicin, 
pyrazinamide and ethambutol) for two months followed by four months of a 
combination of isoniazid and rifampicin. The rise of multi-drug resistant TB (MDR-
TB) and extensively drug resistant TB(XDR-TB) further necessitates prolonged 
therapy and the addition of second and third line antibiotics such as aminoglycosides, 
fluoroquinolones and macrolides. These drugs are often poorly tolerated, ineffective 
against drug-resistant TB or have toxic side effects due to the required prolonged 
treatments (up to 24 months), thereby leading to significant morbidity and 
mortality[40]. 
Although previously thought to be benign environmental microbes, Non-Tuberculous 
mycobacteria (NTM) are increasingly observed over the past decade, as a cause of 
infections worldwide[41, 42]. This paradigm shift in NTM prevalence is presumably 
due to higher environmental exposure rates to such mycobacteria, increased selective 
pressure imparted by intensive antibiotic use in patients, autophagy-inhibition-
associated reduction in host immunity after prolonged antibiotic treatment or patient-
to-patient transmission[43, 44]. Mab, a distant relative of Mtb and Mlep[45, 46]is a 
free-living nontuberculous mycobacterium commonly found in water and soil, which 
causes skin and soft-tissue infections and pulmonary diseases, particularly in patients 
with lung disease (such as cystic fibrosis) or a previous history of tuberculosis[47, 48]. 
A single-centre retrospective study of CF patients showed an increase in incidence of 
NTM infections from 0 to 9% over a period from 2002 to 2011[49].  
After several changes in nomenclature and subspecies differentiation over recent 
years, the M.abcessus complex is now considered to comprise three distinct 
subspecies: M.abcessus subsp. abscessus, M.abcessus subsp. massiliense and 
M.abcessus subsp. bolletii [47, 50, 51]. High virulence and resistance to chemotherapy 
of Mab complex is attributed to a combination of intrinsic and acquired resistance 
mechanisms. The intrinsic resistance of Mab and other mycobacteria to drugs results 
from factors such as low permeability of the mycobacterial cell envelope acting 
synergistically with antibiotic inducible internal systems like drug-efflux pumps, 
antibiotic-inactivating enzymes, target-modifying enzymes and genes providing metal 
resistance [52-54]. Acquired resistance is frequently associated with spontaneous 
mutations of antibiotic target genes, although alteration in function of one or more 
other genes may also be involved[52, 53].  
The current clinical management of Mab infection in CF is highly challenging due to 
the high rates of resistance of the bacterium to antibiotics and most of the classical 
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anti-tuberculosis drugs[45]. Further, owing to its resistance to most commonly used 
disinfectants, various outbreaks of Mab infections in clinical and post-surgical settings 
have been reported[55]. Current treatment involves prolonged therapy using antibiotic 
combinations such as clarithromycin, amikacin, and cefoxitin, which are often poorly 
tolerated and lead to toxic side effects[47]. Hence, there is an urgent need of effective 
drugs to treat Mab infection. 
For the Mab proteome there are greater challenges, due to the poor annotation of the 
Mab genome leading to 4920 predicted protein coding sequences[54], nearly one 
thousand more than for Mtb (3959 coding sequences), and the availability of only 39 
experimentally defined structures in the Protein Data Bank (PDB)[56, 57]. A 
preliminary modelling exercise has predicted structures of over 3000 of these 
genes[58] & [Malhotra, S & Blundell, TL: unpublished]. 
 
Fragment Screening for Mycobacterium abscessus  
Our approach to lead discovery for Mab targets has been centred on the experience 
gained with the Gates Foundation HIT-TB and EU-FP7 MM4TB Mtb programmes. To 
develop the Mab fragment-screening programme it was fundamental to identify 
essential gene products in this organism that have either a known crystal structures or 
alternatively an orthologue of a known structure, where we already had an Mtb FBDD 
programme. This strategy led to targeting PurC (SAICAR synthase), an enzyme 
involved in bacterial de-novo Purine biosynthesis and TrmD (tRNA-(N
1
G37) methyl 
transferase), an essential tRNA modifying enzyme in bacteria, by reproducing the 
known Mab 3D structures, and selecting CoaD/PPAT (Phosphopantethiene adenylyl 
transferase), where we had a programme for Mtb funded by the Gates Foundation 
HIT-TB.  
Phosphopantetheine adenylyltransferase (PPAT) catalyzes the penultimate step in the 
biosynthesis of CoA in prokaryotes. Coenzyme A (CoA), an essential co-factor for 
many cellular enzymes involved in biosynthetic, degradative and metabolic pathways, 
acts as an important acyl group carrier for all organisms[59]. The biosynthesis of CoA 
consists of a five-step reaction catalysed by different enzymes and utilizing 
pantothenate (Vitamin B5), cysteine and ATP[60] as starting substrates. PPAT 
enzyme is a member of the nucleotidyltransferase α/β phosphodiesterases superfamily 
and catalyses the reversible transfer of an adenylyl group from ATP to 4’-
phosphopantetheine (Ppant) to yield 3’-dephospho-CoA (dPCoA) and pyrophosphate, 
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as shown in Figure 2A. dPCoA in turn is phosphorylated by dephospho-CoA kinase 
(DPCK) to generate CoA[61, 62].  
Although some bacteria are capable of de novo pantothenate synthesis, others utilize 
extracellular pantetheine for the biosynthesis of CoA. Nonetheless, all intermediate 
pathways converge at the penultimate step of CoA biosynthesis catalysed by 
PPAT[63]. Studies of CoA pathway intermediates in Escherichia coli showed that 
pantothenate and 4’-phosphopantetheine (Ppant) accumulated in the cell, suggesting 
an important rate-limiting role of PPAT in the pathway that may be crucial to its 
potential as an antibiotic target[63-65]. In higher eukaryotes, the final two steps of 
CoA biosynthesis are catalysed by a single bi-funtional enzyme called CoA synthase, 
containing a PPAT like domain. The marked structural differences between bacterial 
and human PPATs further suggest the potential for this bacterial enzyme as a novel 
antibiotic target[66-68]. 
The previously determined PPAT structures from various bacterial species such as 
Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, Enterococcus 
faecalis, Burkholderia pseudomallei and Mab demonstrate the presence of a canonical 
Rossmann fold as seen in many dinucleotide binding proteins. Attempts to develop 
PPAT inhibitors targeting E-coli PPAT enzyme, using HTS and combinatorial 
synthesis were only partially successful as none of the resulting candidate compounds 
showed inhibitory activity at the cellular level[69, 70]. A high throughput screening of 
the AstraZeneca compound library and subsequent structure-guided lead optimization 
led to the development of a set of compounds that significantly reduced the bacterial 
burden of gram-positive bacteria such as S. pneumoniae and S. aureus both in vitro 
and in animal models of infection[71]. However, these compounds were not 
progressed into clinical development owing to unfavorable toxicity and 
pharmacokinetic profiles. 
We have built on the fragment-based drug discovery campaign against Mtb PPAT, 
which has led to the development of potential lead compounds having binding 
affinities to Mtb PPAT in the low micromolar range (Jamal, E. B., Blaszczyk, M., 
Blundell, T.L. & Abell, C. unpublished). We solved the crystal structures of Mab 
PPAT in apo form (PDB code: 5O06), and in a binary complex with the enzyme 
product, 3’-dephospho Coenzyme A (PDB code: 5O08). Having a working 
crystallization system, we then initiated a structure-guided fragment-based drug 
discovery campaign against Mab focused on this target. 
The crystal structure shows that the biologically active hexameric form of Mab apo-
PPAT consists of two trimers, as seen with all known PPATs from bacteria[72-77]. 
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Each subunit consists of a canonical Rossmann fold[78] made of five parallel β-
strands surrounded by six α-helices (Figure 2B & C).  
The three-dimensional structure of Mab PPAT in complex with the reaction product, 
3’-dephospho Coenzyme A (dpCoA) shows a similar binding mode to the one 
previously observed for Mtb PPAT, where dpCoA binds to all six sub-units of the 
hexamer[79]. The reaction product spans the large active-site cavity of Mab PPAT and 
adopts a ‘bent’ conformation upon binding, as has been previously observed with 
PPAT: dpCoA structures from other bacterial species[72-77] (Figure 2C & D). 
A structural superposition of Mab PPAT:Apo and Mab PPAT:dpCoA shows large 
conformational changes in the flexible loop II (residue range 36-46) that connects β-
strands β2 and α-helix α2 as well as loop IV (residues 87-99) at the base of the active 
site (Figure 2D & E). In Mab PPAT:dpCoA structure, loop II is found to have shifted 
towards the active site by about 7Å, when measured at C atom of Lys41, as 
compared to its position in Mab PPAT:Apo structure (Figure 2D & E). This large shift 
in loop II positions the invariant catalytic Lys41 residue favorably within H-bonding 
distance of adenylate -phosphate (2.8 Å) and 4’-phosphate (2.9Å) of dpCoA 
respectively.  
The initial fragment screening of the Cambridge in-house library, consisting of 960 
fragments, was performed on Mab PPAT, using differential scanning fluorimetry. 
Thirty fragments from the library showed a difference in unfolding temperature 
greater than 1
o
C upon PPAT binding. For the validation of these fragment hits, the 
structure of each was investigated by X-ray crystallography, resulting in crystal 
structures of PPAT in complex with fragments at resolutions ranging from 1.4 to 1.9 Å 
for 18 out of 30 fragment hits studied. The fragments were found to occupy four 
distinct binding sub-pockets within the PPAT active site, as shown in (Figure 3C & 
D). These fragments included examples that occupy the binding sites for adenylyl and 
4’-phosphopantetheine regions of dpCoA, thereby spanning the entire active site 
groove of PPAT. Sub-pockets I & II correspond to the indole and ribose phosphate 
binding regions of dpCoA respectively whereas III & IV correspond to pantothenate 
and -mercaptoethylamine sites of dpCoA respectively. Binding of fragments is 
mediated by several strong and weak hydrogen bonds, -interactions as well as 
hydrophobic and ionic contacts. Figure 4 shows the detailed binding mode of 6 
representative fragment hits at sites I to IV. 
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Many fragments engage key residues, such as His17, Arg90, Val125, Ser9, Leu73 
involved in substrate binding and transition state stabilization of PPAT[72], in 
addition to making new interactions. Fragments binding to sites I & II, for example, 
mimic some of the strong -interactions to side chains of Arg 90 and His 17 and 
hydrogen bonding interactions to the back bone amide of Gly 88, mediated by the 
adenylyl part of dpCoA (Figures 3A & 4). PPAT binding to dpCoA was found to 
result in considerable ordering and rearrangement of the loop IV to two complete -
helical turns at the N-terminal of helix4. Several fragments also lead to a similar 
conformational switching of loop IV near the base of the catalytic site of PPAT as 
shown in Figures 2E & 3B. Fragments at site III and IV recapitulate interactions of 
4’-phophospantetheine arm of dpCoA, such as hydrogen-bonding contacts mediated 
by the side chains of Lys41, Ser9, Asn38 and Glu132 as well as hydrophobic contacts 
to Leu 73, Met101 and Leu129, in addition to several water-mediated hydrogen bonds 
at the PPAT active site (Figures 3A & 4). 
 
The fragments were further characterized by isothermal titration calorimetry. The 
thermodynamics of the fragment-binding events showed that many were associated 
with very low heat changes, which may be attributed to a lower enthalpic contribution 
to binding, as previously reported for Mtb PPAT-ATP, where interactions are likely 
driven by entropic component of displacement of water molecules in the active 
site[80].  For fragment interactions that resulted in a reasonable binding isotherm, the 
measured dissociation constants were greater than or equal to 500M (example shown 
in Figure 5B), while fragment 2 afforded an average Kd of 66M (Kd1= 37.3 µM, Kd2 
= 83.3 µM, Kd3 = 72.5 µM, Kd4 = 76.3 µM, Kd5 =13.9 µM and Kd6 = 114 µM), where 
the data were fitted using a six-site sequential binding model (Figure 5C). 
Interestingly, fragment 2 adopts a dual binding mode where two molecules each of the 
fragment bind to each subunit of PPAT hexamer, at sub-pockets I and II respectively 
(Figures 3D & 4B).  
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Fragment Binding & Hotspot Maps 
We further analyzed the binding propensities of PPAT protein to ligands with the help 
of the hotspot-mapping program developed by Radoux and co-workers [81]. Hotspots 
are often defined as areas within the protein that provide relatively large contributions 
to the overall binding affinity of ligands[82, 83]. These regions not only satisfy the 
minimum binding requirement for fragments but also maintain the original fragment 
binding interactions when elaborated. The importance of hydration thermodynamics is 
becoming increasingly recognized as a driving force for fragment binding to target 
proteins[84]. It has been hypothesized that hotspot regions are characterized by the 
presence of water molecules having restricted translational and rotational freedom 
owing to their location within a hydrophobic cavity or close to a patchwork of 
hydrogen bonds and lipophilic amino-acid sidechains. Ligand binding that displaces 
such water molecules leads to a favorable free-energy change mainly due to an 
entropic contribution [84]. The hotspot-mapping program identifies interactions that 
drive fragment binding by a global search of the protein structure, calculating grid- 
based atomic propensities for specific donor, acceptor and hydrophobic interactions. 
This is followed by weighting the propensity scores based on buriedness of the grid 
points and sampling of the weighted atomic scores using three simple molecular 
probes to create corresponding donor, acceptor and hydrophobic hotspot maps[81].  
While the observed fragment hits satisfy many of the predicted protein-hotspot 
interactions, the map contoured at a lower level suggests potential ways to elaborate 
the fragments to reach those hotspot regions that are not yet explored (Figure 5A). For 
example, fragment 2 is found to be mediating the donor and acceptor hotspots via 
hydrogen bonds to backbone carbonyl of Gly88 by the indazole NH and to active site 
Ser9 and Phe10 via the carboxylic acid moiety, at sub-pockets I and II respectively. 
Similarly, fragment 4 is found to satisfy the predicted H-bond acceptor interactions 
through the mandelic acid moiety forming H-bond to Ser9 and active site water 
molecules and the phenoxy group of the fragment making hydrophobic contact to 
Leu73. These fragments may be further elaborated in the direction of the hotspots 
corresponding to interactions with Asn105, Thr113 and Glu98 at the base of the active 
site, as shown in Figure 5A. 
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‘Fragment-like’ Drugs against Mycobacterial species 
Many critical drugs in current chemotherapy regimen against Mtb are indeed smaller 
than ‘drug-like’ having molecular weights in the range of 100-300 daltons. These 
include anti-tuberculosis drugs like isoniazid (INH), ethionamide (ETH) and para-
aminosalicylic acid (PAS), which are still found to be useful against drug-susceptible 
TB, as well as pyrazinamide (PZA) a key relapse-reducing drug. Though these drugs 
require fairly long treatment periods and are less effective against drug-resistant Mtb, 
it is intriguing how these small molecules have retained their killing effect over nearly 
a century from the time they were developed. Gopal et al[85] in a recent review 
suggest that molecules that are small, reactive and promiscuous have certain 
advantages over larger, single-target drugs that may render these molecules effective 
against mycobacterial species. Compounds like INH, ETH and PZA for example, 
owing to their small size and promiscuity are more likely to be accepted as substrate 
analogues and metabolized by bacterial enzymes turning these prodrugs into more 
reactive compounds capable of hitting multiple-targets, resulting in irreversible 
damage to the cell. Being small (MW<300Da) and moderately lipophilic (clogP <3) 
also allows easy penetration of these molecules through the otherwise highly 
impermeable mycobacterial cell envelope, leading to higher in-vivo exposure and 
favorable pharmacokinetic properties[86, 87] [85].  
Based on this idea, Moreira and co-workers in a recent study[88] identified 38 
fragment hits having bactericidal activity against Mtb (MIC50< 500 µM), from 
screening a fragment library of 1725 compounds. Interestingly, 23 out of the 38 
identified hits were shown to have bactericidal activity against M. avium and 13 hits 
against Mab as well.  These hits retained their favourable pharmacokinetic properties 
and a good fraction of the hits were found to be selective against mammalian cells, 
though no structure-activity relationship could be established.  
Fragment-like molecules were found to potentiate the effect of ethionamide (ETH), a 
second line TB drug, by 10-fold and showed significant intrinsic bactericidal activity 
in the absence of ethionamide in a study done by Nikiforov and co-workers[89]. Here, 
Fragment 1 (MEC = 3 ± 1.8 μM) was identified from screening an in-house library of 
1250 fragments against Mtb EthR using a cascade of biochemical, biophysical and 
structural biology approaches. EthR, a transcriptional repressor belonging to TetR 
family, controls the expression of Flavin-dependent, monooxygenase enzyme EthA 
which in turn activates ethionamide., a second-line anti-TB drug. 
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Subsequent structure activity relationship (SAR) exploration around fragment 1 and its 
analogue 2 led to the development of the potent ethionamide boosters, the amide 14 
(MEC = 0.4 ± 0.2 μM) and the carbamate 28 (MEC = 0.4 ± 0.2 μM), which represent 
approximately 7-fold improvement in boosting the effect of ethionamide in Mtb 
culture from the starting fragment 1 (MEC = 3 ± 1.8 μM). Further, compounds 14 and 
28 showed significant intrinsic bactericidal effect in the absence of ethionamide with 
(IC50 ≈ 1 μM) and exhibited low nanomolar activity in macrophage assays in the 
presence of ethionamide[89]. 
 
Chemical Elaboration of Fragments for M. tuberculosis  
For the second stage of FBDD involving elaboration of fragments by growing, 
merging or linking strategies, we seek to develop a structure-guided approach using 
the range of biochemical, structural, thermodynamics and kinetic methods. Chemical 
optimization of fragments involves an iterative process where analysis of binding 
interactions as well as biophysical, in-vitro and in-vivo functional testing of the 
optimized analogues are done to inform further chemical modifications until a 
significantly potent lead compound is obtained. 
Because the fragment-elaboration for the Mab PPAT target is ongoing, we use 
examples of the fragment-merging approach that was successfully applied in our lab 
and elsewhere to develop small molecule inhibitors of Mtb.  
 
(i) Fragment merging to develop inhibitors against Mtb EthR. 
A fragment-merging approach to develop small molecule inhibitors of Mtb EthR led to 
the development of a potent lead candidate in a recent study[90]. EthR is a 
physiological dimer having a large hydrophobic binding cavity but containing a 
number of H-bond acceptors and aromatic residues capable of directed  π interactions; 
the starting fragments 1 & 2 were each found to occupy two distinct sites thus filling 
the entire cavity as shown in Figure 6A & B. Merging of Fragments 1 & 2 further 
resulted in a significantly potent lead molecule, compound 15 (Figure 6C) affording 
an IC50  of 3μM[90].  
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 (ii) Fragment elaboration to inhibit a Mtb cytochrome P450 (CYP) enzyme 
A fragment elaboration approach by Hudson & co-workers led to the development of 
high affinity ligands against CYP121, a cytochrome P450 (CYP) enzyme[91]. The 
mycobacterial genome encodes for at least 20 different CYPs that play an important 
role in virulence and survival of the bacteria[92]. CYPs belong to a family of mono-
oxygenase enzymes containing heme as a co-factor that catalyze the oxidation of 
organic molecules and thereby mediate diverse metabolic processes. CYP121 is found 
exclusively in Mtb and helps in the production of mycocyclosin, a secondary 
metabolite, by catalyzing the formation of a C-C bond between the two tyrosine 
residues of the substrate cyclodityrosine (cYY). Rv2276, the gene encoding for 
CYP121, was found to be an essential Mtb gene, suggesting that the product 
mycocyclosin has an important cellular role or an overproduction of the substrate cYY 
is toxic to the organism[93, 94]. A fragment screening approach that combines 
fluorescence-based thermal shift assay, NMR (STD and WaterLOGSY) and X-ray 
crystallography helped in the identification of 4 hits from a fragment library of 665 
compounds adopting two distinct binding modes[95].  
Elaboration of these fragments hits resulted in several promising derivatives (Figure 
6D). In particular, the two different binding conformations of fragment 10 (Kd 
=1.7mM) was exploited to synthesize compound 12. Although this was less active 
than the starting fragment, further replacement of its five-membered ring with an 
aminopyrazole led to compound 13 with a Kd of 40 M. Growth of compound 13 into 
the water-filled cavity of CYP121 resulted in compound 14, with an additional phenol 
ring which mediated further H-bonds with the active site water molecules, improving 
the affinity by over 100-fold from the starting fragment (Kd of 15 M,)[91, 95, 96]. 
Elaboration of the lead compound 14 by Kavanagh and colleagues and the addition of 
a 3amino-phenyl group at the meta position of the aromatic ring attached to five-
membered ring, led to compound 15 (Kd of 0.015M, LE=0.41), the highest affinity 
inhibitor of CYP121 to date as shown in Figure 6D [97]. 
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(iii) Inhibiting Mtb Thymidylate kinase 
Thymidylate kinase (TMK) is an enzyme that belongs to the DNA synthesis pathways 
and that produces thymidine 5’-diphosphate using ATP and thymidine 5’-
monophosphate. This enzyme is an established drug target and has been the focus for 
many drug discovery campaigns against different pathogens, in both eukaryotes[98] 
and prokaryotes, including Mtb[99, 100] and also viruses[101]. The essentiality of this 
enzyme is established in Mtb and drug discovery efforts with this target identified a 
number of inhibitors some of them with active in cell based assays. However, the vast 
majority of the compounds obtained are analogues of thymidine and contain a 
thymidine moiety[100]. To move away from these scaffolds, Naik and colleagues 
carried out a fragment screening of TMK, combining biochemical assay and NMR, 
which resulted in the identification of a 3-cyanopyridone containing fragment for 
chemical elaboration[102]. The mode of binding of this fragment hit was determined 
by molecular docking. Subsequent development of the fragment, supported by X-ray 
crystal structures of key compounds, allowed the development of nanomolar-potency 
lead compounds against TMK that retained high ligand efficiency. These compounds 
were found to have different binding modes from the substrate analogues and some 
were found to inhibit Mtb in whole cell assays.  
 
CONCLUSIONS 
The use of protein structure, defined by experimental and computational approaches 
for renin and HIV protease, developed for target identification, validation and 
development of new leads in the 1980s and 1990s, has provided a paradigm for use of 
structural biology to underpin drug discovery.  The progress in structure-guided drug 
discovery has been impressive, but there remain many challenges for the future. They 
lie not only in more efficient exploration of biological and chemical space at the 
molecular level, but also in understanding the many aspects of cell and whole 
organism biology that affect ligand transport, permeability and metabolism, as well as 
the changes in complex assemblies over space and time. 
Progress in defining biological space requires more efficient approaches to improve 
experimental structures. This may come from X-ray methods using conventional 
crystallisation techniques and from X-ray small angle scattering. However, some of 
the most exciting new developments have come from single-particle cryo-EM 
methods, for example those developed with the new powerful electron microscopes 
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such as the FEI Titan Krios transmission electron microscope (TEM) combined with 
direct electron detectors[103], and new software such as RELION[104], which carries 
out 2D image classification followed 3D reconstruction. These revolutionary changes 
have allowed binding of antibiotics to be envisaged on ribosome particles[105] [106]. 
This approach will be particularly powerful at defining structures of the complex 
systems involved in cell regulation and signalling, where interfacial inhibitors or 
stabilisers are of interest. 
Experimental methods of defining biological and chemical space will likely continue 
to be challenging even for organisms with relatively small genomes. Structures are 
required to define interactions of macromolecular and small ligands with proteins. The 
impacts of strain variation, including mutations that are selectively advantageous in 
evolution as well as disadvantageous in disease, will need to be understood at the level 
of protein structure. Thus, it is inevitable that computational methods will need to be 
improved not only to predict the structures and dynamics of monomers and their 
interactions with small molecules, but also the multicomponent systems often 
involving proteins that are intrinsically disordered in parts or the whole of their 
polypeptide chains; these are still very challenging. 
As we have seen, fragment-based drug discovery has improved the exploration of 
chemical space, especially where targets are well described in terms of structure. 
Fragments that are stably bound and maintain their positions during elaboration bind 
at hotspots. Some progress has been made in recognising these from the structure as 
we have described, for example Radoux et al., 2016 [81]. It is now becoming clear that 
there is wide range of interaction types in addition to H-bonds and simple lipophilic 
interactions, including π-π, π-δ-positive and π-δ-negative charge, and these can 
be displayed using software such as Arpeggio [107] & Intermezzo [Ochoa-Montaño, 
B., Blundell, T.L., unpublished].  
Fragment-based approaches have proved successful in getting drugs to the market in 
cancer, and the lessons learnt are proving helpful in the design of antimicrobials, as we 
have described. The FBDD approach allows efficient exploration of the chemical 
space against targets like those of mycobacteria, where features, such as the bacterial 
cell wall, demand the investigation of molecules that are likely different - in size, 
lipophilicity and other properties - than those optimised for human protein targets.  
Advances in protein crystallography using high-throughput, roboticized approaches at 
synchrotrons offer further opportunities. Frank von Delft and colleagues have 
developed automated methods to soak crystals with fragments and mount them in the 
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X-ray beam.  Perhaps the most impressive advance has been in PanDDA[108], a 
method that reveals subtle differences when the ligand is partially occupied. The 
PanDDA method reveals electron density for only the changed state, even from poor 
models and inaccurate maps, by subtracting a proportion of the apo state, accurately 
estimated by averaging many apo-protein crystals.  
Fragment based approaches can screen a vast chemical space using a relatively small 
library of fragments with a set of desired physiochemical properties that can be 
retained and controlled during the structure-guided optimization of the fragment hits. 
Finding inhibitors against mycobacteria is a highly challenging task due to the 
impermeability of cell wall, multidrug efflux-pumps and drug modifying enzymes that 
these organisms possess. Small hydrophilic molecules are known to cross the 
mycobacterial cell wall through porins but large macrocycles and small hydrophobic 
molecules also diffuse through the cell wall, resulting in TB drugs being widely 
distributed across chemical space[109]. Solving the structure of efflux pumps in these 
organisms will surely provide insights into the efflux mechanisms and help identify 
chemical scaffolds that are extruded from cells, thereby allowing FBDD approaches to 
optimise the chemistry of new lead molecules. 
The structure-guided fragment-based approach avoids the requirement for large 
screening libraries and provides a route to the discovery of new therapeutics for 
diseases that lead to many deaths throughout the world and gives hope for effective 
medicines for rare diseases and those that affect the large populations of less affluent 
parts of the world. Knowledge of protein structure has contributed to the development 
of early stages of drug discovery and is widely exploited in both industry and 
academia. 
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ACCESSION NUMBERS: Coordinates and structure factors have been deposited in 
the Protein Data Bank with accession numbers: 5O06; 5O08; 5O0A; 5O0B; 5O0C; 
5O0D; 5O0F; 5O0H. 
 
Figure Legends: 
Figure 1: A) Schematic to illustrate the concept of drug discovery by exploring biological 
space encompassing genome information to identify new targets, followed by exploration of 
chemical space using screening libraries based on knowledge of the target. Target protein in 
the illustration: HIV-1 proteinase (PDB code: 3PHV), Drug: HIV proteinase inhibitor: 
saquinavir (Roche) B) Fragment Based Drug Discovery workflow illustrated as four stages 
involving 1.Target Identification and protein production 2.Fragment library screening 3. Hit 
validation and 4. Iterative fragment elaboration cycle through to a potential lead candidate. 
Various tools and techniques involved at each stage of the process are also shown. 
 
Figure 2: A) Schematic depicting bacterial Coenzyme A biosynthetic pathway. The 
penultimate step catalyzed by PPAT enzyme is boxed and the gene names corresponding to 
each enzyme is given in brackets. Many organisms are capable of exogenous uptake of the 
starting substarte Pantothenate, while some bacteria and fungi undertake de-novo Pantothenate 
synthesis from β-alanine and Pantoate, catalysed by Pantothenate synthetase (panC). PPCS* 
and PPCDC* activities residue within a single polypeptide chain in bacteria. B) Crystal 
structure of Mab PPAT:Apo solved at 1.5Å resolution showing a hexameric assembly. C) 
Protomer of Mab PPAT bound to dpCoA (purple ball & stick representation) forming a ‘bent’ 
conformation at active site. The secondary structure elements are coloured with β-strands in 
yellow, - helices in red and loop regions in green. D) Structural superposition of Mab 
PPAT:Apo (green) and Mab PPAT:dpCoA (blue) at C

 atoms showing conformational 
changes in the flexible loop II and loop IV. dpCoA, represented as spheres, is seen bound to 
all the three protomers in the asymmetric unit. E) Enlarged view showing conformational 
changes at loop II positioning the invariant catalytic Lys41 residue close to adenylyl -
phosphate of dpCoA (shown in pink stick representation) and ordering of loop IV to two 
complete -helical turns at the N-terminal of helix4 at the base of catalytic site along with 
inward flipping of the Arg90. Other invariant residues interacting with DpCoA, His17 and 
Ser9 are also shown. The figures were prepared using Pymol (PyMOL Molecular Graphics 
System, Version 1.7 Schrödinger, LLC). PDB codes: Mab PPAT:Apo: 5O06, Mab 
PPAT:dpCoA: 5O08. 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 21 
Figure 3: A) Active site diagram showing binding interactions of dpCoA shown in pink ball 
and stick model and the active site residues as green lines. Hydrogen bonds are represented 
with blue dotted lines, -interactions in black dotted lines, hydrophobic contacts in red dotted 
lines. B) Overlay of Mab PPAT:Apo (green) and Mab PPAT: fragment 1(orange) structures 
showing conformational changes in loop IV invariant Arg90, His17 and Ser127 are 
represented in blue lines.  D & C) Structural Superposition of six Mab PPAT structures bound 
to fragments 1(purple), 2(gold), 3(green), 4(blue), 5(salmon) and 6(turquoise), showing 
fragments occupying four distinct regions (I-IV) in the PPAT active site shown in surface 
electrostatic representation. (PDB codes: 5O0A, 5O0B, 5O0C, 5O0D, 5O0F, 5O0H).The 
figures were prepared using Pymol (PyMOL Molecular Graphics System, Version 1.7 
Schrödinger, LLC) and Intermezzo (Ochoa-Montaño, B., Blundell, T.L. et al unpublished; 
Jubb, H.C., et al, 2017 [105]).  
 
Figure 4: Active site diagram of Mab PPAT showing binding interactions of fragments 1-6 
(shown in orange ball and stick model) from A to F respectively and the active site residues as 
blue lines. Fragment contacts are represented as dotted lines, hydrogen bonds are represented 
in blue, -interactions in black, hydrophobic contacts in red and ionic contacts in green dotted 
lines respectively. The figures were prepared using Pymol (PyMOL Molecular Graphics 
System, Version 1.7 Schrödinger, LLC) and Intermezzo (Ochoa-Montaño, B., Blundell, T.L. 
et al unpublished; Jubb, H.C. et al, 2017[105]). (PDB codes 5O0A, 5O0B, 5O0C, 5O0D, 
5O0F, 5O0H) 
 
Figure 5: A) Hotspot map (Radoux et al, 2015) [79] of Mab PPAT:Apo protein with Mab 
PPAT structures bound to fragments 1(purple), 2(gold), 3(green), 4(blue), 5(salmon) and 
6(turquoise), overlaid. The hydrophobic hotspot map is shown in yellow, donor and acceptor 
hotspots are shown as blue and red surfaces respectively. The major residues mediating 
interactions at the hotspots are shown in white stick representation. B) Representative 
thermodynamic profile for fragment binding to Mab PPAT. The figures were prepared using 
Pymol (PyMOL Molecular Graphics System, Version 1.7 Schrödinger, LLC). (PDB codes: 
5O0A, 5O0B, 5O0C, 5O0D, 5O0F, 5O0H) 
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Figure 6: Fragment elaboration to develop inhibitors of Mtb. A) Fragment merging approach 
to develop small molecule inhibitors of Mtb EthR. The region corresponding to the 
hydrophobic binding cavity of EthR dimer is boxed. B) binding pocket of EthR where the 
starting fragments 1 (in gold) & 2 (in grey) were each found to occupy two distinct sites in two 
copies thereby filling the entire cavity involving sub-pockets I, II, II and IV (marked in blue) 
C) Merging of Fragments 1 (in gold) & 2 (in grey) results in a significantly potent lead, 
compound 15 (green). The corresponding thermal shift and IC50values for each compound are 
also illustrated. PDB codes: 5FIJ, 5F27, 5F0F. D) Fragment elaboration to develop compounds 
that inhibit Mtb CYP121. Two molecules of Fragment 10 (green) binds CYP121 near the 
Heme (yellow) binding pocket. Subsequent merging and elaboration of fragment 10, via 
compounds 13 and 14 (blue), led to the development of potent compound 15 (pink). The 
corresponding Kd and Ligand efficiency values for each compound are also illustrated. PDB 
codes (4G47, 4KTL, 5IBE). The figures were prepared using Pymol (PyMOL Molecular 
Graphics System, Version 1.7 Schrödinger, LLC). 
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